Thank line XX X. adjusted update you, end and Ginger, provided and the Fourth on on quarter low of range EPS came with our June the near morning. good in September in
by growth currency macroeconomic X.X% health environment, on prior further slowdown a in year. driven COVID-XX-related growth reflected This business in $X.X results includes basis. we a respiratory Our challenging Overall, events, consumer constant and our a billion sales care shifting behaviors, lower in the delivered versus contributions.
$XXX was strong was on retail in constant saw accruals tax performance, legal year. growth The the GAAP onetime delivered The to underlying charge basis. and U.S. U.S. that higher pharmacy Boots noncash net loss Remember a transformational of pharmacy grew COVID-XX profitability rent lower million cost by results was certain program. XX% charges related $XXX leaseback impairment to million retail U.K. contributions, business accruals, loss of net regulatory incentive charges quarter. ago growth. from the improved sale currency in our business and and million $X.XX driven by and by year improved rate.
We settlements positive XX% we of decline XX.X% and down management Adjusted lower lower gains, quarter prior compared in a X.X% Our EPS driven health and $XXX international for sales care. a had
to $X.XX on Fiscal a highlights. XX.X% 'XX constant move of Now basis. down currency currency the year-to-date increased was basis. Adjusted constant on let's sales EPS X.X% a
in performance and charge loss the U.S. COVID-XX by These accruals, for were a labor $X.X increased net lower fiscal to 'XX of in claims contributions and reflected and incentive investments. 'XX. challenges offset compared Fiscal lower billion results after-tax earnings opioid-related retail billion net lawsuits. growth $X.X GAAP $X.X in Our was international included partly billion
Now reflecting levels Retail contributions mix sales lower script of comp a let's move higher profit impact gains, to sale in the leaseback pharmacy growth. our quarter, Pharmacy incentive reflecting XX% was underlying lower XX.X% growth was lower from COVID-XX from higher and impact Comp X.X%, contributed impacts a AOI. and rent, brand XX% positively AOI down and in inflation the business to and pharmacy U.S. of accruals gross segment. net
weaker-than-normal to during sales of growth.
A brand the respiratory inflation resulted a X.X% impact comp in U.S. market weaker prescription quarter. in now turn mix redeterminations impacts and me overall driven the by Medicaid pharmacy and season comp and quarter, script increased Let pharmacy,
administered showed comp data COVID-XX year XX% down vaccinations million XXX,XXX weaker activity compared from the year prior in roughly scripts quarter grew prior the these cold trends, respiratory market down X.X%, Third-party quarter. quarter. Despite immunizations.
We excluding and X.X in flu, the to
Excluding profit adjusted prior increased fourth of the period. the COVID-XX, year quarter impact versus gross
our to next Turning business. U.S. retail
the quarter, was macroeconomic respiratory continued driven business weaker-than-normal environment. by retail behaviors, by consumer a impacted season shift a and the During challenging a in
weaker the sales approximately in impact; As impacted growth XXX main customers reflecting we cough, first, kits decline XX approximately second, cold, by basis in basis a environment. drivers: the were an impacted XXX result, from comparable challenging lastly, had seasonal sales COVID-XX X.X% weakness, quarter.
There to spending, points basis around macroeconomic flu an back continue pull summer on and three test XX% as by points are declined points; discretionary
of top basis the COVID-XX 'XX, nearly cough, XXX prior was the category cold, while in and kits. performance, pressure shrink both sales impacted points flu XXX single gross on saw grew wellness, by second beauty margin seasonal higher-margin grew margin elevated and Retail and increase health a and in in test digits. in at decline a Looking personal gross Despite fiscal low such a care in we as year. categories, point the half, basis lower by
International next U.K. growth These improved in year to currency wholesale higher numbers. XX%. impacts increased XX%, outpacing increased delivering I always, segment, growth disciplined and ahead to was growth segment Boots performed constant income Sales all from prior up profit again pharmacy continued improved, nearly and of the in operating very sales strong growth. well in guidance. adjusted period. a the Germany percentage Boots The as Turning resulted U.K. sales will as markets. management. and talk cost margin of across X.X%, X.X%.
Gross SG&A quarter, with compared increased grew inflation costs, store-related retail experienced Despite benefiting International profit the XX.X% and international of
quarter, health Boots.com the in on the increased details year year-on-year of the Boots represented tenth quarter. a in at grew prior approximately grew XX% U.K.. gains market in XX% retail beauty comp wellness. year Comp consecutive over and our sales with XX.X%, and retail look U.K. top sales. share versus percentage XX.X% now quarter, for Let's prior point X Boots sales and more of
both sales higher U.S. reflecting to sales businesses.
Segment XX%, of up business and XX% provided on by the pro Summit segment $X and EBITDA the forma results on basis. up clinic grew Shields forma billion, $XX of sequentially. pro growth of by sales billion, $X.X pro to lives, growth footprint The expansion guidance profit XX% as Adjusted gross value-based line year acquisition in quarter of on loss forma were volumes CareCentrix, the driven delivered Healthcare. Health fourth up in basis, VillageMD, by XX% scale was acquisition and led clinics mature. growth fee-for-service next of June EBITDA and of rapidly all forma the AOI improvement The pro from quarter. of of an $XXX sales was XX, Turning sales VillageMD with a prior the year-over-year. a increased with improved continues a XX%. with million, sequentially Segment million Healthcare and U.S. were adjusted CareCentrix
reflecting payments Turning the of cash capital was 'XX, billion driven in compared flow in flow. operating fiscal next We growth $XXX VillageMD lower $X.X cash This $X.X to Healthcare settlement Fiscal contributions, losses 'XX expenditures of the our to and COVID-XX segment. generated U.S. opioid of the free year. prior flow approximately micro rollout. billion in initiatives, by million million. increased including $XXX resulted by This and fulfillment center cash
$X.X by in fiscal debt reduced also billion We 'XX.
of cash As approximately number reduced expenditures Ginger in turn optimization actions taking fiscal discussed, $XXX in million $XXX approximately are working our drive now fiscal to benefit capital guidance. will we from in improvement flow including capital million initiatives.
I 'XX a free to and 'XX,
$X.XX to from EPS guiding of $X.XX, $X.XX fiscal 'XX are We 'XX. in fiscal adjusted to down
rate a respiratory the year. will contributions. on I a that in We're macroeconomic consumer performance, underlying to higher the also assuming season and we lower contributions, discussing sale tax leaseback face headwinds continued some and 'XX. Before pressure want lower weaker and compared key prior fiscal These include mention COVID-XX to
Excluding our be the is primarily around scale, profitability segment expect which in two headwinds accelerating to breakeven. our driven by underlying expected assumes U.S. impact healthcare EBITDA in First factors: these to at business forecast of XXXX growth, adjusted with continues the or as we
income immediate in modest operating be and retail to to pharmacy the actions cost both improve base adjusted expect we U.S. pharmacy. growth retail Second, underlying driven and by underlying
notable year-on-year EPS. the estimated pieces is between XX%. impact bridge mentioned to headwinds 'XX. to and as of Sale have to fiscal a to from me I larger Let XX% negative now illustrate we adjusted 'XX fiscal moving three leaseback
expect international leaseback rates fiscal we compared from points repeat by that expected XX not are beyond do higher in any Tax recognized XXXX and be and 'XX. contribution before, benefits to due sale XXXX As we XXXX. will XXXX, have to increasing higher said approximately rates in in not percentage to
X% to that contributions in result year-on-year projecting lower impact. COVID-XX we're a Finally, X%
impacts, to base accelerating driven care we cost U.S. XX%, and expect by improve actions to the of profitability in health company. Excluding growth our across X% these immediate underlying
we in Adjusted be on to XX% income X% the a is constant through to detail. you in down operating 'XX expected to be currency X% guidance walk XXXX total a now X% me sales basis. constant to basis. greater on Let up fiscal Overall, expect currency
the for percentage X%. and leaseback negatively be points Let AOI me Retail percentage guidance approximately roughly contributions now to X and each segments, sales walk of XX U.S. up you and lower lower by of with impacted COVID-XX starting gains. sale U.S. to pharmacy. assumptions be through our reporting flat projected Pharmacy from the segment points will retail are
the X% AOI now impacts, take underlying drive drivers. key to XX% is will business Excluding you business these growth.
I through projected the to
SG&A, we be calendar Quarter-to-date, headwind administered First, On by adopting we track performance benefit COVID driven million XXXX, million percentage Within overall as 'XX.
We're penetration.
At in savings we the signed reimbursement in $X 'XX program shrink, reimbursement, last cost already during of category a do been months over challenging represent the retail, retail season a already has in across milder projecting projecting billion fiscal described. brand planning a a XX% market fiscal year-on-year, XXXX. continues systemic margins we're over in serious volume Ginger anticipate to due flu has We're increasing achieve time, X prudent We less OTC have kit growth for we're expect vaccinations. trends same script on second X and flat roughly well half which contract In roughly 'XX. that COVID improvement we approximately also continued of a and We point X to test fiscal own approach. see in level several lower industry. impacted increase cold, fiscal higher year We're and from our of growth. to sales and volume expect consumer vaccinations a COVID the expect the the continuation comparable a than have cough, of to of XXXX. issue of to the pressure pressure. and
projected to sales are guidance a segment. to Turning next the X% basis. flat for Segment International up currency on constant
the of transactions Chile. operating XX%. 'XX, year-on-year constant expect not $XXX million, We is repeated, representing by currency of million business driven adjusted decline XX% which will the property income be pending decline sales fiscal to to of $XXX in during a entirely and The
execution we Boots impacts, X%, back those business the growth pressures. Excluding with continued up retail of held U.K. by expect be within to to flat AOI impact inflationary
let's U.S. Now turn Healthcare. to
on focused in driving are We performance improved XXXX. U.S. Healthcare financial for
expect will expense outsized fiscal midpoint is in VillageMD, the fiscal million. that growth $X.XX.
The expected of expected quarter of business of an health approximately $X.X growth million by driven of Health first full-risk 'XX XX%, XX% and of to growth XX% clinical to have business represents the prior driven We of 'XX, five year footprint sales quarter, trial growth, adjusted recognized growth Health robust and this the billion by guidance statutory breakeven of 'XX XXXX. range. of cost in reflecting $XX at first management.
We international the increase be $XXX year Shields factors see services $XXX an all by pro volume, to $X.X forma year-over-year through are to in tax benefits the Summit to to first expect fiscal and the businesses.
On decrease a effective billion, million in the XX% quarter's adjusted to at EBITDA to at be and EPS we optimization ongoing basis, by increase of the higher repeat cost we of year. This and and sales realignment compared rates with in XXXX not lives, impact fee-for-service lapping Interest assume clinic Walgreens base rate tax driven an and are scaling following our to care approximately expected In full
prior tax first the repeat year period, which will had not in a First, we in quarter significant XXXX. of benefit
lower be the contributions year's we're last Second, and in expecting quarter, wave to omicron seasonality. first COVID-XX reflecting
in activity. Fourth, our from we and of elevated pharmacy Third, we're contributions lower levels sale staff. leaseback lapping labor anticipate investments
more the early in we start quarter flu expect season Finally, 'XX, in normalized peaking also year. a versus the prior second in fiscal the
see Moving the discuss the improvement, first I will sequential four and quarter, will beyond drivers. we top
the start a base. to year adjusted First, on the the but There series to we're $X.XX balance first EPS lower benefit of quarter. of of is in impact cost ramp These first to second the our limited $X.XX will in actions quarter. executing to have the quarter, will compared
profitability clinic panels our in Healthcare from expect costs. patient realigning improve U.S. we and Second, footprint, the optimizing growing segment, to
including expansion margin retail growing we improving retail initiatives, expect sequentially comps programs. Third, from contributions and
season seasonality holiday profit height when business, benefiting significant Finally, plays over is our of role quarter, U.S. which by and U.S. care a to it sees the let cough, health cold, in flu usually to season.
With second hand is now our driven the that, me John the Boots the in U.K. the discuss business.
